BioSpace News Archive

Trials underway at five laboratories and two diagnostic equipment companies

OptimizeRx Corp. has uplisted to the Nasdaq Capital Market, with its common stock to commence trading on the exchange beginning Friday, June 22, 2018 under the symbol, “OPRX.”

Patient enrollment proceeding under amended protocol

RespireRx Pharmaceuticals Inc. announces the decision of Dr. James S. Manuso to resign as president, CEO, Vice Chairman and member of the Board of Directors (“Board”) of the Company, effective as of September 30, 2018

Alder BioPharmaceuticals, Inc. announced that it will present updated data from the PROMISE 1 and PROMISE 2 phase 3 clinical trials for eptinezumab, Alder’s lead investigational product candidate for migraine prevention, at the upcoming American Headache Society (AHS) annual scientific meeting

Vitality Biopharma, Inc. announced that it has received approval from both the U.S. Drug Enforcement Administration (DEA) and the State of California Research Advisory Panel which permits the Company to continue development of its novel cannabinoid pharmaceutical prodrugs.

Innovest Global Inc. replaced its longstanding corporate website

NewLink Genetics Corporation announced that updated data for patients with diffuse intrinsic pontine glioma (DIPG) from NLG2105, a Phase 1 study evaluating indoximod in combination with radiation and chemotherapy for the treatment of pediatric patients with progressive brain tumors, will be presented at the International Symposium on Pediatric Neuro-Oncology (ISPNO)

Diamond Equity Research has initiated coverage of Oragenics Inc.

Smoke Cartel, Inc. announced they have enlisted the services of BlueCheck, an age and identity verification company for tobacco and vapor products.